Cellectis SA (NASDAQ:CLLS) – Investment analysts at Oppenheimer issued their FY2023 earnings estimates for shares of Cellectis in a research note issued to investors on Tuesday, March 12th. Oppenheimer analyst H. Singh anticipates that the biotechnology company will post earnings per share of $3.68 for the year. Oppenheimer currently has a “Buy” rating and a $44.00 target price on the stock.
CLLS has been the subject of a number of other research reports. Goldman Sachs Group initiated coverage on Cellectis in a research report on Wednesday, December 19th. They issued a “neutral” rating and a $25.00 price target for the company. ValuEngine cut Cellectis from a “buy” rating to a “hold” rating in a research report on Friday, November 16th. BidaskClub cut Cellectis from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 21st. Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Thursday, January 3rd. Finally, Barclays reiterated a “buy” rating and set a $50.00 price objective on shares of Cellectis in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $32.00.
A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in Cellectis by 24,158.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 48,517 shares of the biotechnology company’s stock worth $1,370,000 after buying an additional 48,317 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in Cellectis in the 3rd quarter worth about $1,120,000. Financial Gravity Companies Inc. acquired a new stake in Cellectis in the 4th quarter worth about $71,000. Point72 Asset Management L.P. boosted its stake in Cellectis by 118.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 156,133 shares of the biotechnology company’s stock worth $4,406,000 after buying an additional 84,533 shares during the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in Cellectis in the 3rd quarter worth about $5,390,000. Hedge funds and other institutional investors own 27.62% of the company’s stock.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Read More: How to Use a Moving Average for Trading
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.